2024-10-19 - Analysis Report
## Regeneron Pharmaceuticals Inc. (REGN) Stock Analysis Report

**Company Overview:** Regeneron Pharmaceuticals Inc. is a biotechnology company that develops and commercializes life-changing medicines for serious diseases. 

**1. Performance Comparison with S&P 500 (VOO):**

* **REGN's Cumulative Return:** 88.97%
* **VOO's Cumulative Return:** 137.88%
* **Performance Gap:** -48.91%
* **Relative Performance:** 28.36% (This means REGN's performance is currently at the 28.36 percentile of its historical performance range compared to VOO.)

**2. Recent Price Movement:**

* **Closing Price:** $990.68
* **5-Day Moving Average:** $1005.53
* **20-Day Moving Average:** $1023.85
* **60-Day Moving Average:** $1103.98

**3. Technical Indicators Analysis:**

* **RSI:** 26.43 (Indicates oversold territory, potential for a rebound)
* **PPO:** 0.04 (Positive, but relatively low, suggesting weak momentum)
* **Delta_Previous_Relative_Divergence:** -27.24 (Indicates a recent downward trend in the relative performance)
* **Expected Return:** 0.0% (This represents the expected long-term return compared to the S&P 500, assuming a long-term holding strategy.)

**4. Recent Earnings and Outlook:**

| Date       | EPS    | Revenue |
|------------|--------|---------|
| 2024-08-01 | 13.25  | 3.55 B$  |
| 2024-05-02 | 6.70   | 3.15 B$  |
| 2023-11-02 | 9.48   | 3.36 B$  |
| 2023-08-03 | 9.05   | 3.16 B$  |

**Most Recent Earnings (2024-08-01):**
* **EPS:** 13.25 (beat analyst estimates)
* **Revenue:** 3.55 B$ (beat analyst estimates)

**Outlook:** Regeneron's recent earnings report suggests continued strong performance, with the company exceeding expectations on both EPS and revenue. The company's pipeline of innovative treatments for serious diseases positions it for sustained growth in the future.

**5. News and Recent Issues:**

**Market Outlook:**  Analyst consensus suggests a bullish outlook for REGN, driven by its strong financial performance, pipeline potential, and a favorable healthcare market environment.

**Analyst Opinions:**  Most analysts are optimistic about REGN, citing the success of its existing products and the promising prospects of its late-stage clinical trials.

**Performance Highlights:** Regeneron's strong product portfolio, including Eylea and Dupixent, has driven consistent revenue growth. Its focus on innovation and expansion into new therapeutic areas further strengthens its position in the market.

**6. Comprehensive Analysis:**

Regeneron Pharmaceuticals Inc. (REGN) is a promising biotech company with a solid track record and a robust pipeline of potential therapies. While its recent performance has lagged behind the broader market, it's important to note that the stock is currently oversold, with indicators suggesting a potential rebound. Regeneron's strong earnings results and future prospects suggest a positive long-term outlook. However, investors should closely monitor the company's progress in clinical trials and upcoming regulatory approvals to gauge its future growth potential.

**7. English Version:** 

This report provides a comprehensive analysis of Regeneron Pharmaceuticals Inc. (REGN) stock. It covers key performance metrics, technical indicators, recent earnings, and market outlook. The analysis suggests a mixed outlook, with the stock currently oversold but boasting strong fundamentals and a promising future. Investors seeking long-term growth potential should consider REGN, while remaining aware of potential near-term volatility and closely monitoring its progress. 
